BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 31158079)

  • 1. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
    Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
    Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
    Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
    Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma.
    Lee SM; Russell A; Hellawell G
    Korean J Urol; 2015 Nov; 56(11):749-55. PubMed ID: 26568792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer.
    Albisinni S; Moussa I; Aoun F; Quackels T; Assenmacher G; Peltier A; Roumeguère T
    Prog Urol; 2019 Apr; 29(5):270-281. PubMed ID: 30954405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
    Mbeutcha A; Shariat SF; Rieken M; Rink M; Xylinas E; Seitz C; Lucca I; Mathieu R; Rouprêt M; Briganti A; Karakiewicz PI; Klatte T
    Urol Oncol; 2016 Nov; 34(11):483.e17-483.e24. PubMed ID: 27646875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
    Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy.
    Yoshida T; Kinoshita H; Yoshida K; Mishima T; Yanishi M; Inui H; Komai Y; Sugi M; Inoue T; Murota T; Fukui K; Harada J; Kawa G; Matsuda T
    Tumour Biol; 2016 Aug; 37(8):10067-74. PubMed ID: 26819209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.
    Zhang GM; Zhu Y; Luo L; Wan FN; Zhu YP; Sun LJ; Ye DW
    Tumour Biol; 2015 Nov; 36(11):8537-43. PubMed ID: 26032095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    Int Braz J Urol; 2019; 45(2):315-324. PubMed ID: 30785697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study.
    Favilla V; Castelli T; Urzì D; Reale G; Privitera S; Salici A; Russo GI; Cimino S; Morgia G
    Int Braz J Urol; 2016; 42(4):685-93. PubMed ID: 27564278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
    Zhang J; Zhou X; Ding H; Wang L; Liu S; Liu Y; Chen Z
    BMC Urol; 2020 Mar; 20(1):31. PubMed ID: 32192483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic values of preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and lymphocyte- to-monocyte ratio for patients with muscle- invasive bladder cancer undergoing radical cystectomy.
    Lei Y; Jiao D; Yao Z; Wang L; Zhao Z
    Arch Esp Urol; 2022 Apr; 75(3):287-294. PubMed ID: 35435163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    Schulz GB; Grimm T; Buchner A; Jokisch F; Grabbert M; Schneevoigt BS; Kretschmer A; Stief CG; Karl A
    Clin Genitourin Cancer; 2017 Dec; 15(6):e915-e921. PubMed ID: 28587816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinicopathological and Prognostic Value of NLR, PLR and MLR in Non-Muscular Invasive Bladder Cancer.
    Chen H; Wu X; Wen Z; Zhu Y; Liao L; Yang J
    Arch Esp Urol; 2022 Jun; 75(5):467-471. PubMed ID: 35983820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy.
    D'Andrea D; Moschini M; Gust KM; Abufaraj M; Özsoy M; Mathieu R; Soria F; Briganti A; Rouprêt M; Karakiewicz PI; Shariat SF
    J Surg Oncol; 2017 Mar; 115(4):455-461. PubMed ID: 28105663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
    Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
    Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy.
    Kawahara T; Furuya K; Nakamura M; Sakamaki K; Osaka K; Ito H; Ito Y; Izumi K; Ohtake S; Miyoshi Y; Makiyama K; Nakaigawa N; Yamanaka T; Miyamoto H; Yao M; Uemura H
    BMC Cancer; 2016 Mar; 16():185. PubMed ID: 26944862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.